NCT05154487 2026-03-03
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
Clinical Trials
8 trialsNCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT04524000 2026-01-12
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT04762979 2026-01-02
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Big Ten Cancer Research Consortium
Phase 2 Active not recruiting
NCT05090358 2025-10-27
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05392608 2025-09-17
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT05625087 2025-08-20
SAFIR 03
UNICANCER
Phase 2 Active not recruiting
NCT04544189 2025-06-18
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting